Background
This appeal arose from a patent interference proceeding between two sets of inventors both claiming rights to poxvirus-based vaccines with deleted or inactivated essential genes. Traditional viral vaccines had focused on deleting inessential genes from the viral vector — genes not required for the virus to replicate — so that a safer, non-infectious particle could be produced. The innovation at issue here was different: it involved deleting or inactivating an essential gene from the poxvirus, creating a viral vector that could only replicate in specially engineered host cells that provided the missing gene product. When injected as a vaccine, the modified poxvirus would infect regular cells, produce immunogenic proteins, but could not produce new infectious viral particles — providing immunity without infection risk.
The Board of Patent Appeals and Interferences declared an interference and ultimately denied Falkner’s priority motion, holding that Falkner could not antedate Inglis’s effective filing date because Falkner’s application did not adequately satisfy the written description requirement under 35 U.S.C. § 112, first paragraph, for the full scope of the interference count. Falkner appealed, arguing that the Board had improperly required specific structural recitations of known biological sequences.
The Court’s Holding
The Federal Circuit affirmed the Board’s denial of Falkner’s priority motion. Writing for the court, the panel addressed a significant legal principle about written description in the biotechnology context: there is no per se rule that an adequate written description of an invention involving a biological macromolecule must contain a recitation of known structure. A patent applicant is not required to describe in the specification what is already well-known in the art.
Because poxvirus genome sequences and the locations of essential genes were matters of public scientific knowledge at the relevant filing date — available in the scientific literature and known to those skilled in the art — an applicant need not copy or recite that known information into the patent specification to satisfy the written description requirement for claims that rely on those known structural details. The written description requirement focuses on whether the applicant adequately described the novel aspects of the claimed invention; it does not require exhaustive repetition of background knowledge already possessed by skilled artisans.
Despite this flexible principle, the court affirmed denial of Falkner’s priority motion on the ground that Falkner’s actual disclosure still failed to adequately support the full scope of the interference count. The holding about written description was therefore a clarification favorable to biotech patent applicants generally, even though Falkner lost on the specific facts of this case.
Key Takeaways
- There is no per se rule in biotechnology patents that written description requires explicit recitation of known structural information (such as genome sequences) — applicants may rely on publicly available scientific literature for what is already well-known in the field.
- The written description requirement in § 112 focuses on whether the applicant described the novel aspects of the invention adequately, not on whether the applicant repeated background knowledge possessed by persons skilled in the art.
- In patent interference proceedings, the priority date a party can claim depends on whether the party’s application satisfies the written description requirement for the full scope of the interference count, not merely for a subset of embodiments.
- Biotechnology patent applicants benefit from knowing they can describe inventions more concisely when working in fields where key structural information (genome sequences, protein structures) is publicly known — they need not reproduce all available scientific data.
- This case is part of the Federal Circuit’s effort to apply the written description requirement in a technically informed way in biotechnology cases, recognizing that the bar for what must be explicitly stated depends heavily on what is already known in the art.
Why It Matters
Falkner v. Inglis provides important guidance for biotechnology patent applicants on the scope of the written description requirement. In the biotech field, the written description doctrine has been the source of considerable uncertainty: how much structural information must an applicant include in a specification to adequately describe a claimed invention? For patents on biological macromolecules — DNA sequences, protein structures, viral genomes — the question has been particularly fraught because detailed structural information can be both voluminous and, in many cases, already available in the scientific literature.
The court’s holding that no per se rule requires explicit recitation of known structures gives biotech applicants meaningful flexibility. When a claimed invention builds on a well-characterized biological substrate (like the poxvirus genome), an applicant need not copy all publicly available sequence data into the specification. Instead, the applicant can focus the written description on the novel features of the claimed invention. This approach aligns the written description requirement with the practical realities of biotechnology research and patent prosecution, and it remains a useful principle for evaluating the adequacy of biotechnology patent disclosures.